Anti-CD20 MONOCLONAL ANTIBODIES IN THE TREATMENT OF MULTIPLE SCLEROSIS: MECHANISMS OF ACTION, CLINICAL EFFICACY, SAFETY, AND CONTEMPORARY THERAPEUTIC PERSPECTIVES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6456Keywords:
Multiple Sclerosis, Anti-CD20, B Cells, Ocrelizumab, Ofatumumab, Rituximab, Ublituximab, Monoclonal Antibodies, Disease-modifying Therapy, SafetyAbstract
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system in which B lymphocytes play a central role in disease pathogenesis. The development of anti-CD20 monoclonal antibodies has transformed the therapeutic landscape of MS by providing highly effective disease-modifying therapies with sustained reductions in relapse activity, magnetic resonance imaging disease activity, and disability progression. This review summarizes the current evidence regarding the biological rationale for B-cell depletion and discusses the mechanisms of action, efficacy, safety, and clinical applications of rituximab, ocrelizumab, ofatumumab, and ublituximab. Particular attention is given to adverse events, including infusion- and injection-related reactions, infections, hypogammaglobulinemia, vaccine responsiveness, and long-term monitoring strategies. Current treatment recommendations and the evolving role of anti-CD20 therapies within contemporary MS management are also reviewed. Overall, anti-CD20 monoclonal antibodies represent a cornerstone of modern MS therapy, offering substantial clinical benefit when combined with individualized patient selection, appropriate monitoring, and preventive measures.
References
Krajnc, N., Bsteh, G., Berger, T., Mares, J., & Hartung, H. P. (2022). Monoclonal antibodies in the treatment of relapsing multiple sclerosis: An overview with emphasis on pregnancy, vaccination, and risk management. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 19(3), 753–773. https://doi.org/10.1007/s13311-022-01224-9
de Sèze, J., Maillart, E., Gueguen, A., Laplaud, D. A., Michel, L., Thouvenot, E., et al. (2023). Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Frontiers in Immunology, 14, 1004795. https://doi.org/10.3389/fimmu.2023.1004795
Kaegi, C., Wuest, B., Crowley, C., & Boyman, O. (2022). Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders. Frontiers in Immunology, 12, 1–16. https://doi.org/10.3389/fimmu.2021.788830
Carlson, A. K., Amin, M., & Cohen, J. A. (2024). Drugs targeting CD20 in multiple sclerosis: Pharmacology, efficacy, safety, and tolerability. Drugs, 84(3), 285–304. https://doi.org/10.1007/s40265-024-02011-w
Galota, F., Marcheselli, S., De Biasi, S., Gibellini, L., Vitetta, F., Fiore, A., et al. (2025). Impact of high-efficacy therapies for multiple sclerosis on B cells. Cells, 14(8), 606. https://doi.org/10.3390/cells14080606
Xie, G., Chen, X., Gao, Y., Yang, M., Zhou, S., Lu, L., et al. (2025). Age-associated B cells in autoimmune diseases: Pathogenesis and clinical implications. Clin Rev Allergy Immunol, 68(1), 18. https://doi.org/10.1007/s12016-025-09021-w
Santana-Sánchez, P., Vaquero-García, R., Legorreta-Haquet, M. V., Chávez-Sánchez, L., & Chávez-Rueda, A. K. (2024). Hormones and B-cell development in health and autoimmunity. Front Immunol, 15, 1385501. https://doi.org/10.3389/fimmu.2024.1385501
Gibiansky, E., Petry, C., Mercier, F., Günther, A., Herman, A., Kappos, L., et al. (2021). Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol, 87(6), 2511–2520. https://doi.org/10.1111/bcp.14658
Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Brochet, B., Naismith, R. T., et al. (2020). Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology, 95(13), e1854–e1867. https://doi.org/10.1212/WNL.0000000000010376
Fox, E. J., Markowitz, C., Applebee, A., Montalban, X., Wolinsky, J. S., Belachew, S., et al. (2018). Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult Scler, 24(14), 1862–1870. https://doi.org/10.1177/1352458518808189
Montalban, X., Matthews, P. M., Simpson, A., Petrie, J. L., Sammon, C., Ramagopalan, S., et al. (2023). Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. Ann Clin Transl Neurol, 10(3), 302–311. https://doi.org/10.1002/acn3.51732
Nawaz, A., Bakhtiyar, A., Khan, M. I., Siddiqui, E., Khan, E., Abbas, M., et al. (2025). Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis. BMC Neurol, 25(1), 514. https://doi.org/10.1186/s12883-025-04519-4
Awada, Z., Hameed, N., & Harel, A. (2024). Profile of ofatumumab in the treatment of multiple sclerosis: Design, development and place in therapy. Drug Des Devel Ther, 18, 5985–5996. https://doi.org/10.2147/DDDT.S315174
Kang, C., & Blair, H. A. (2022). Ofatumumab: A review in relapsing forms of multiple sclerosis. Drugs, 82(1), 55–62. https://doi.org/10.1007/s40265-021-01650-7
Martin, S. J., Guenette, M., & Oh, J. (2024). Evaluating the therapeutic potential of ublituximab in the treatment of MS: Design, development and place in therapy. Drug Des Devel Ther, 18, 3025–3042. https://doi.org/10.2147/DDDT.S388410
Preziosa, P., Brescia Morra, V., Capobianco, M., Gasperini, C., Grimaldi, L. M. E., Marfia, G. A., et al. (2025). Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: Current evidence and expert opinion. J Neurol, 272(10), 707. https://doi.org/10.1007/s00415-025-13442-0
Filippini, G., Kruja, J., & Del Giovane, C. (2025). Rituximab for people with multiple sclerosis. Cochrane Database Syst Rev, 3(3), CD013874. https://doi.org/10.1002/14651858.CD013874.pub3
Brancati, S., Gozzo, L., Longo, L., Vitale, D. C., & Drago, F. (2021). Rituximab in multiple sclerosis: Are we ready for regulatory approval? Front Immunol, 12, 661882. https://doi.org/10.3389/fimmu.2021.661882
Alvarez, E., Longbrake, E. E., Rammohan, K. W., Stankiewicz, J., & Hersh, C. M. (2023). Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Multiple Sclerosis and Related Disorders, 79, 105009. https://doi.org/10.1016/j.msard.2023.105009
Elgenidy, A., Abdelhalim, N. N., Al-kurdi, M. A. M., Mohamed, L. A., Ghoneim, M. M., Fathy, A. W., et al. (2024). Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: A systematic review and meta-analysis of 19,139 multiple sclerosis patients. Frontiers in Neurology, 15. https://doi.org/10.3389/fneur.2024.1380654
Saidha, S., Bell, J., Harold, S., Belisario, J. M., Hawe, E., Shao, Q., et al. (2023). Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 44(5), 1515–1532. https://doi.org/10.1007/s10072-022-06582-y
Otero-Romero, S., Lebrun-Frénay, C., Reyes, S., Amato, M. P., Campins, M., Farez, M., et al. (2023). ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Multiple Sclerosis (Houndmills, Basingstoke, England), 29(8), 904–925. https://doi.org/10.1177/13524585231168043
Santangelo, O. E., Provenzano, S., Vella, C., Fermi, S., Facchini, L., Rizzo, M., et al. (2024). Safety and efficacy of vaccinations in patients with multiple sclerosis: A systematic review. European Review for Medical and Pharmacological Sciences, 28(16), 4179–4198. https://doi.org/10.26355/eurrev_202408_36670
Landtblom, A. M., Berntsson, S. G., Boström, I., & Iacobaeus, E. (2021). Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand, 144(3), 229–235. https://doi.org/10.1111/ane.13453
Selmaj, K., Hartung, H. P., Mycko, M. P., Selmaj, I., & Cross, A. H. (2024). MS treatment de-escalation: Review and commentary. J Neurol, 271(10), 6426–6438. https://doi.org/10.1007/s00415-024-12584-x
Bittner, S., Kriegel, M. A., Siegmund, B., Kümpfel, T., & Sabat, R. (2025). Treatment options for the comorbidity of multiple sclerosis with other chronic inflammatory diseases. Deutsches Arzteblatt International, 122(16), 427–432. https://doi.org/10.3238/arztebl.m2025.0088
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mateusz Kałwik, Iga Klepacz, Paweł Mikołajczak , Tomasz Szwarc , Dominika Groth, Wiktoria Dubiel , Aleksandra Lorent, Martyna Rykowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
